Shares of Savara Inc (NASDAQ:SVRA) shot up 3.2% during trading on Monday . The company traded as high as $1.46 and last traded at $1.30, 11,526 shares were traded during mid-day trading. A decline of 98% from the average session volume of 528,234 shares. The stock had previously closed at $1.26.
SVRA has been the topic of a number of analyst reports. Evercore ISI set a $17.00 price objective on shares of Savara and gave the stock a “buy” rating in a research note on Monday, August 12th. LADENBURG THALM/SH SH reissued a “hold” rating and issued a $1.00 target price on shares of Savara in a report on Thursday, October 3rd. Finally, Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Savara currently has an average rating of “Hold” and a consensus target price of $9.09.
The company has a 50 day moving average price of $0.93 and a 200-day moving average price of $3.20. The company has a current ratio of 13.07, a quick ratio of 13.07 and a debt-to-equity ratio of 0.23. The company has a market cap of $53.99 million, a P/E ratio of -1.02 and a beta of 0.27.
Several hedge funds have recently made changes to their positions in SVRA. GSA Capital Partners LLP acquired a new position in Savara in the 2nd quarter valued at approximately $206,000. United Capital Financial Advisers LLC acquired a new position in Savara during the 2nd quarter worth about $61,000. DekaBank Deutsche Girozentrale lifted its holdings in Savara by 67.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock worth $50,000 after buying an additional 8,300 shares during the period. Farallon Capital Management LLC lifted its holdings in Savara by 43.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,475,000 shares of the company’s stock worth $8,236,000 after buying an additional 1,050,000 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of Savara in the 2nd quarter valued at about $59,000. 40.42% of the stock is currently owned by hedge funds and other institutional investors.
About Savara (NASDAQ:SVRA)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: What is basic economics?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.